Developing a tool for noninvasive monitoring of renal allografts.
Renal transplantation has emerged as the therapy of choice for many patients with end-stage renal disease. One of the major goals is to tailor immunosuppressive therapy to the individual needs of every patient at every time point post transplant, balancing the risk for rejection and over-immunosuppression. Such individualized treatment will require assays that can detect harmful processes in the allograft early and that can be measured repeatedly. In this review, advantages and disadvantages of current assays to monitor renal allografts noninvasively and how proteomic technology might contribute to the development of novel biomarkers to improve patient management will be discussed.
Schaub
Stefan
S
University Hospital Basel, Department for Transplantation Immunology and Nephrology, Petersgraben 4, 4031 Basel, Switzerland. schaubs@uhbs.ch
Wilkins
John A
JA
Rush
David
D
Nickerson
Peter
P
D000818:Animals; D015415:Biomarkers / Q000032:analysis; D016903:Drug Monitoring / Q000379:methods*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000379:methods* / Q000592:standards; D040901:Proteomics / Q000379:methods; D014184:Transplantation, Homologous
D015415:Biomarkers; D007166:Immunosuppressive Agents